This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HAMBURG, Germany, March 19, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) is going to broadcast its press & analyst conference in Frankfurt live on the internet. The Management Board will inform you about the FY 2012 results as well as about the status of the discovery alliance business and the partnerships of the development projects. Moreover, they will provide the status of "Action Plan 2016 – Innovation Efficiency" and present an outlook for fiscal year 2013. The conference will be held in English.
Tuesday, 26 March 2013
09.00 am CET (08.00 am GMT/04.00 am EDT)
To join the
audio webcast and to access the
presentation slides you will find a link on our home page
www.evotec.com shortly before the event.
For those who prefer to listen to the presentation via
phone, please dial:
+49 (0)69 20 17 44 210
+44 207 153 9154
+1 877 423 0830
The on-demand version of the webcast will be available on our website:
www.evotec.com >Investors> Events> Financial Calendar.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes and with Roche in the field of Alzheimer's disease. For additional information please go to
FORWARD LOOKING STATEMENTS — Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Evotec AG:
Gabriele Hansen, Head of Corporate Communications